Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-95
Vinorelbine Tartrate
Cat. No.
AKA-95
CAS No.
125317-39-7
MF
C53H66N4O20
MW
1079.1
Vinorelbine ditartrate is an anti-mitotic agent which inhibits the proliferation of Hela cells.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
Vinorelbine Tartrate
CAS No.
125317-39-7
MF
C53H66N4O20
MW
1079.1
Specification
98%
Research Area
Oncology
Description
Vinorelbine ditartrate is an anti-mitotic agent which inhibits the proliferation of Hela cells. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Chen J, et al. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cellular & Molecular Immunology. 2023 Jan;20(1):51-64. PMID: 36447031.
[2]. Chia S, et al. CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Reports. Medicine. 2025 Apr 2:102053. PMID: 40187357.
[3]. Zhang J, et al. Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. Science Advances. 2023 Jun 2;9(22):eadc9273. PMID: 37256945.
[2]. Chia S, et al. CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Reports. Medicine. 2025 Apr 2:102053. PMID: 40187357.
[3]. Zhang J, et al. Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. Science Advances. 2023 Jun 2;9(22):eadc9273. PMID: 37256945.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-384
Tedizolid phosphate
CAS No.: 856867-55-5
MF:C17H16FN6O6P
AKA-383
Brivaracetam
CAS No.:357336-20-0
MF:C11H20N2O2
AKA-382
Cobimetinib Fumarate
CAS No.:1369665-02-0
MF:C46H46F6I2N6O8
AKA-379
Bempedoic acid
CAS No.:738606-46-7
MF:C19H36O5
AKA-378
Borofalan(10B)
CAS No.:80994-59-8
MF:C9H12BNO4
AKA-377
AkProva™ Metildigoxin
CAS No.:30685-43-9(acetone-free)
MF:C42H66O14.1/2C3H6O
AKA-376
AkProva™ beta-Acetyldigoxin
CAS No.:5355-48-6
MF:C43H66O15
AKA-375
Ak-NucleoVia™ Agrostemmoside E
CAS No.:2656438-29-6
MF:C84H128O45
AKA-374
Novobiocin sodium
CAS No.:1476-53-5
MF:C31H35N2NAO11
AKA-360
Travoprost
CAS No.:157283-68-6
MF:C26H35F3O6
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
